Duloxetine in fibromyalgia: rejection. Marketing authorization rejected and rightly so.
The European marketing authorization committee has ruled against the utilisation of duloxetine (Cymbalta) in the treatment of diffuse idiopathic polyalgic syndrome, alias fibromyalgia. A coherent position, given this psychotropic drug's unfavourable risk-benefit balance.
D017277:Drug Approval; D005060:Europe; D005356:Fibromyalgia / Q000188:drug therapy*; D006801:Humans; D013876:Thiophenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D013876:Thiophenes